Abstract
Background and aims:
Lixisenatide, a once-daily prandial glucagon-like
peptide-1 receptor agonist, reduces postprandial (PP) glycaemic excursions
and HbA
1c
. We report an exploratory analysis of the GetGoal-M and S trials
in patients with type 2 diabetes mellitus (T2DM) with different changes in PP
glucagon levels in response to lixisenatide treatment.
Materials and methods:
Patients (n=423) were stratified by their change in
2 hour PP glucagon level between baseline evaluation and Week 24 of treat
-
ment with lixisenatide as add-on to oral antidiabetics (OADs) into groups
of Greater Change (GC; n=213) or Smaller Change (SC; n=210) in plasma
glucagon levels (median change -23.57 ng/L). ANOVA and Chi-squared tests
were used for the comparison of continuous and categorical variables, respec
-
tively. Baseline and endpoint continuous measurements in each group were
compared using paired
t
-tests.
Results:
Mean change from baseline in 2 hour PP glucagon levels for the
GC vs SC groups was -47.19 vs -0.59 ng/L (p<0.0001), respectively. Patients
in the GC group had a shorter mean duration of diabetes (7.3 vs 9.0 years;
p=0.0036) and lesser OAD use (4.5 vs 5.7 years; p=0.0092) than those in
the SC group. Patients in the GC group had a greater mean reduction in
HbA
1c
(-1.10 vs -0.67%; p<0.0001), fasting plasma glucose (FPG; -25.20 vs
-9.30 mg/dL [p<0.0001]), PP plasma glucose (PPG; -129.40 vs -78.22 mg/dL
[p<0.0001]), and a greater drop in weight (-2.27 vs -1.17 kg; p=0.0002) and
body mass index (-0.84 vs -0.44 kg/m
2
; p=0.0002) than those in the SC group.
More patients in the GC group also achieved composite endpoints, including
HbA
1c
<7% with no symptomatic hypoglycaemia and no weight gain (40.38
vs 19.52%; p<0.0001), than in the SC group.
Conclusion:
Greater reductions in PP glucagon associated with lixisenatide
as add-on to OADs in patients with T2DM are also associated with greater
reductions in HbA1c, FPG, PPG, and greater weight loss, highlighting the
importance of glucagon suppression on therapeutic response.
Clinical Trial Registration Number: NCT00712673; NCT00713830
Supported by: Sanof
Original language | English |
---|---|
Article number | 846 |
Pages (from-to) | S344 |
Number of pages | 1 |
Journal | Diabetologia |
Volume | 57 |
Issue number | Suppl.1 |
Early online date | 19 Aug 2014 |
DOIs | |
Publication status | Published - 30 Sept 2014 |
Event | 50th EASD Annual Meeting - Vienna, Austria Duration: 15 Jun 2014 → 19 Sept 2014 |
Bibliographical note
Abstracts of the 50th EASD Annual Meeting50th EASD Annual Meeting, Vienna, Austria, 15-19 September 2014